New hope to tame dangerous transplant complication
Disease control
Recruiting now
This trial is testing a drug called ruxolitinib as the first treatment for acute graft-versus-host disease (GVHD), a serious complication where donor cells attack the body after a bone marrow transplant. It will compare ruxolitinib alone to standard steroid treatment for lower-ri…
Phase: PHASE2 • Sponsor: John Levine • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC